Inhibition of the Cardiac Angiogenic Response to Surgical FGF-2 Therapy in a Swine Endothelial Dysfunction Model

Background—Discrepancy exists between the potent effects of therapeutic angiogenesis in laboratory animals and the marginal results observed in patients with advanced coronary artery disease. In vitro and small animal data suggest that angiogenesis may depend on locally available nitric oxide (NO), but the impact of endothelial dysfunction on therapeutic angiogenesis in the myocardium has been unclear. We compared the effects of clinically applicable angiogenesis methods in swine in which endothelial dysfunction was experimentally induced to that observed in normal swine. Methods and Results—Miniswine were fed either a regular (N=13) or hypercholesterolemic diet (N=13) for 20 weeks. Hypercholesterolemic swine showed coronary endothelial dysfunction on videomicroscopy. Animals from both groups received 100 &mgr;g of perivascular sustained-release fibroblast growth factor (FGF)-2 in the lateral myocardial territory, previously made ischemic by placement of an ameroid constrictor around the circumflex artery. After 4 weeks of FGF-2 therapy, lateral myocardial perfusion was significantly lower in hypercholesterolemic than in normocholesterolemic swine, both at rest and during pacing (0.44±0.04 versus 0.81±0.15 mL/min/g at rest, respectively; P =0.006; and 0.50±0.06 versus 0.71±0.10 mL/min/g during pacing; P =0.02). Hypercholesterolemic swine showed no net increase in perfusion from FGF-2 treatment. Endothelial cell density and FGF receptor-1 expression were significantly lower in the lateral territory of hypercholesterolemic versus normocholesterolemic animals. Conclusions—The cardiac angiogenic response to FGF-2 treatment using clinically applicable methods was markedly inhibited in hypercholesterolemic swine with coronary endothelial dysfunction. These findings suggest that coronary endothelial dysfunction is major obstacle to the efficacy of clinical angiogenesis protocols and constitutes a target toward making angiogenesis more effective in patients with advanced coronary disease.

[1]  W. Cohn,et al.  Endogenous myocardial angiogenesis and revascularization using a gastric submucosal patch. , 2003, The Annals of thoracic surgery.

[2]  F. Sellke,et al.  Vascular growth factors and angiogenesis in cardiac surgery. , 2003, The Annals of thoracic surgery.

[3]  J. Paramo,et al.  Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. , 2002, Atherosclerosis.

[4]  U. Förstermann,et al.  Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. , 2002, Nitric oxide : biology and chemistry.

[5]  J. Ware,et al.  Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. , 2002, The Journal of thoracic and cardiovascular surgery.

[6]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[7]  W. Sessa,et al.  Distinction between signaling mechanisms in lipid rafts vs. caveolae , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[9]  J. Cooke,et al.  Angiogenesis Is Impaired by Hypercholesterolemia: Role of Asymmetric Dimethylarginine , 2000, Circulation.

[10]  R O Bonow,et al.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.

[11]  R. Rizza,et al.  Attenuated in vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypercholesterolemia. , 1999, Hypertension.

[12]  F. Sellke,et al.  Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. , 1998, Circulation.

[13]  S. Higano,et al.  Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. , 1998, Circulation.

[14]  F. Sellke,et al.  Comparison of VEGF delivery techniques on collateral-dependent microvascular reactivity. , 1998, Microvascular research.

[15]  A. Quyyumi,et al.  Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. , 1997, Journal of the American College of Cardiology.

[16]  R. Schwartz,et al.  Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. , 1997, Circulation.

[17]  R Bicknell,et al.  Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.

[18]  R. Schwartz,et al.  The effect of basic fibroblast growth factor on coronary vascular tone in experimental hypercholesterolemia in vivo and in vitro , 1997, Coronary artery disease.

[19]  F. Sellke,et al.  Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. , 1996, The American journal of physiology.

[20]  S Amerini,et al.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. , 1994, The Journal of clinical investigation.

[21]  W Grossman,et al.  Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. , 1994, The Journal of clinical investigation.

[22]  W. Hauck,et al.  Quantitating error in blood flow measurements with radioactive microspheres. , 1989, The American journal of physiology.

[23]  K. Zitnay,et al.  Loss of Selective Endothelial Cell Vasoactive Functions Caused by Hypercholesterolemia in Pig Coronary Arteries , 1988, Circulation research.

[24]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[25]  Osamu Kawakami.  BASIC FIBROBLAST GROWTH FACTOR , 2006 .

[26]  J. Schrader,et al.  Endothelial dysfunction of coronary resistance vessels in apoE-/- mice involves NO but not prostacyclin-dependent mechanisms. , 2002, Cardiovascular research.

[27]  L. Lerman,et al.  Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. , 2001, Atherosclerosis.

[28]  F. Prinzen,et al.  Blood flow distributions by microsphere deposition methods. , 2000, Cardiovascular research.